Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Point and Figure Charting -- Ignore unavailable to you. Want to Upgrade?

To: Berk who wrote (8329)	10/7/1998 10:52:00 AM
From: Dennis J.	Respond to of 34824

CTSL Biotechs Hi Dick, Yes, I agree with you. Michael Murphy's long-term record is ok, but many of his picks are way down, probably because they are smaller-caps, and until recently, biotechs were out of favor. His research is strong, and he provides a good shopping list, complete with monthly updates. I use the newsletter to learn about the sector, and for earnings estimates and stock price targets. Where else can you get this so neatly packaged together? Now the big challenge. Which picks to buy? Enter p&f, of course! I have put Murphy's favorites into a list in AIQ, which I monitor frequently. I expect the best picks will be confirmed by p&f and other TA's (money flow, on-balance-volume, stochastics). Only with good indications from p&f, then do you buy. What is your modus operandi? Keep in touch. Dennis